MBX Biosciences director Hoerter proposes $268K sale
The sale includes an amount necessary to cover a tax obligation from settlement of a vested equity award distribution.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MBX Biosciences, Inc. director Steven L. Hoerter reported a proposed sale of 4,893 common shares, with an approximate sale date of November 10, 2026 and an aggregate market value of $268,248.45. Fidelity Brokerage Services LLC is listed as the broker. Hoerter acquired the shares from the issuer through restricted stock vesting on November 6, 2026, as compensation. The sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Key Figures
Key Terms
Restricted Stock Vesting financial
Aggregate Market Value financial
attorney-in-fact regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.